David Muench is currently the New Target Validation Lead at Eli Lilly and Company, where they leverage their expertise in quantitative single cell technologies and molecular immunology/oncology. With a proven track record of developing clinical stage molecules, David has demonstrated exceptional leadership in directing cross-functional teams and streamlining project timelines. Their academic background includes a Master's in Bioengineering and a Ph.D. in Molecular and Developmental Biology from the University of Louisville and the University of Cincinnati College of Medicine, respectively. David's previous roles include Research Scientist and Senior Research Scientist at Eli Lilly, as well as various research positions at Cincinnati Children's Hospital Medical Center and the University of Louisville.
This person is not in any teams
This person is not in any offices